App-Quantinova.ai

Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.

Kirsty Taylor - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

N/A

Integrative molecular profiling and response to chemotherapy on the COMPASS trial.

Grainne M. O'Kane - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Microphthalmia, syndromic, 9

N/A

The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Daniel John Renouf - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ticilimumab

Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.

Akina Natori - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Baseline anemia in patients with biliary tract cancer (BTC) and its association with survival: A retrospective cohort study.

Mark Doherty - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Regional variation in the costs of treating curative gastric cancer.

Yunni Jeong - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.

Maxine Kish - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Extrahepatic cholangiocarcinoma

N/A

The prognostic role of neutrophil-to-lymphocyte ratio trends during therapy in esophageal cancer.

Yaseen Al Lawati - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.

Michael Lee - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

A real-world comparison of multi-modality therapies in locally advanced gastro-esophageal junction (GEJ) cancers.

Haider Samawi - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.

Eileen Mary O'Reilly - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Ticilimumab

Symptom burden at the end of life for neuroendocrine tumors: A population-based analysis of patient-reported outcomes.

Julie I. Hallet - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

Outcomes of patients with borderline-resectable pancreatic cancer treated with FOLFIRINOX versus gemcitabine plus nab-paclitaxel.

Shaina D'Lee Templeton - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreato-biliary malignancies

Gemcitabine

Real-world outcomes among patients (pts) treated with gemcitabine (GEM)-based therapy post-FOLFIRINOX (FFOX) failure in advanced pancreatic cancer (APC).

Erica S Tsang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreato-biliary malignancies

Gemcitabine

Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliative and functional outcomes—Final results of a prospective clinical trial.

Yaacov Richard Lawrence - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreato-biliary malignancies

Morphine

Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC).

Di Maria Jiang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

An updated retrospective review of the safety and efficacy of sorafenib for recurrent hepatocellular carcinoma post-liver transplantation.

Sophie Feng - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).

Daniel E. Meyers - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Sorafenib

Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.

David Chan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Temozolomide

Pancreatic adenocarcinoma in young adults (≤45 years old): Characteristics and clinical outcomes from a Canadian center.

Antoine Desilets - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Filters

28841 Abstracts